AZN · story · 26 October
AstraZeneca · 15 headlines from 15 outlets, on 26 October 2026.
Many outlets report CLARITY-Gastric01 data showing the drug doubled survival.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Times Now is the largest at 10.0, ahead of Health and Me (10.0).
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Times Now | 10.0 |
| Health and Me | 10.0 |
| Briefs Finance | 10.0 |
| FirstWord Pharma | 10.0 |
| TOKENPOST | 10.0 |
| Bloomberg | 10.0 |
| Seeking Alpha | 10.0 |
| Reuters | 10.0 |
| GenomeWeb | 10.0 |
| TipRanks | 10.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Times Now | 1 | +10.0 |
| Health and Me | 1 | +10.0 |
| Briefs Finance | 1 | +10.0 |
| FirstWord Pharma | 1 | +10.0 |
| TOKENPOST | 1 | +10.0 |
| Bloomberg | 1 | +10.0 |
| Seeking Alpha | 1 | +10.0 |
| Reuters | 1 | +10.0 |
| GenomeWeb | 1 | +10.0 |
| TipRanks | 1 | +10.0 |
| Outlet | Headlines | Average tone |
|---|---|---|
| SRN News | 1 | +10.0 |
| Stock Titan | 1 | +10.0 |
| Yahoo Finance | 1 | +10.0 |
| AD HOC NEWS | 1 | +8.3 |
| Fierce Biotech | 1 | +1.7 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | Late-stage trial showed survival twice as long. |
| +10.0 | Positive phase 3 survival result in gastric cancer |
| +10.0 | Doubled survival, big new franchise potential |
| +10.0 | ADC doubles overall survival in gastric cancer |
| +10.0 | Experimental drug doubled survival |
| +10.0 | Experimental drug doubled survival time |
| +10.0 | Trial shows stomach cancer treatment gave twice the survival. |
| +10.0 | Drug extends overall survival in late-stage trial |
| Tone | What the article reported, and why it scored that way |
|---|---|
| +10.0 | ADC improves survival in gastric cancer patients |
| +10.0 | Positive phase III gastric trial results |
| +10.0 | Drug clears survival bar in late-stage study |
| +10.0 | Median survival doubled to 10 months |
| +10.0 | 42% lower death risk in gastric cancer trial |
| +8.3 | Survival data reported, share price mentioned |
| +1.7 | Data called robust but PFS miss raises regulatory questions |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.